Cancer is caused due to the mutations in the genes – it is a disease of genes. Just like every human body, each person’s cancer is unique. However, the overall genetic makeup of a particular cancer tumor and the patient is not taken into consideration in the standard approach to the cancer treatment. It results in the failed therapies or aggressive relapse. Thus, it is important that genetic architecture of the cancer tumor is studied extensively before deciding the treatment plan.
This is where genetic screening plays a crucial role. DGL has introduced a high-precision test to screen the cancer – Exacta.
Exacta unfolds the deepest genetic secrets of an individual patient’s cancer by accurate, multi-coordinate analysis of all 22,000 genes in the cancer genome. Exacta reaches the depths of cancer’s mechanisms through 100s of millions of data points. It helps to reveal the driver mutations and pathways that are propelling a particular person’s cancer and can be targeted with precision drugs. Exacta thus enables a highly sophisticated treatment strategy beyond conventional perspective. This is the unmatched strength of Exacta. Exacta is the latest and world’s best molecular analysis for difficult cancers.
How does the test help?
It reports all pathways as per KEGG database to identify the most appropriate gene targets for therapy.
Indication of therapy resistance / Angiogenic / Proliferation / Metastatic / Recurrence Potential.
Gene expression of Primary and Metastasis tumours.
Whole exome analysis of Primary and Metastasis (all NCCN recommended genes and more).
Analysis of all miRNA in the cancer genome.
Whole genome analysis of mtDNA (Primary and Metastasis)
Mutation burden and telomere attrition / compromise.
Tests cytotoxic drug response / resistance of cancer genome.
Screens Germline metabolic response to cytotoxic / small molecule therapy.
Detects loss of Hetrozygosity / Micro Satellite Instability / epigenetic indicators.
This test is important where –
- The First Line Therapy has failed
- Relapse of the cancer
- High grade or metastatic cancer
- The Risk of Therapy Failure is high.
It is now indeed important for cancer patients to undergo the screening before rushing into any treatment which may pose a severe threat to the health. Being well-informed helps in taking correct decisions.